top of page
1703143941GxvsD.jpg

INDUSTRY UPDATE

WHAT’S NEW

Dose Optimisation of Mesalazine in Ulcerative Colitis

In ulcerative colitis (UC), treatment goals have evolved beyond symptom control to include objective measures of disease activity, such as biomarker normalisation, endoscopic, etc.¹ These treat-to-target principles highlight the need for regular non-invasive assessment of symptoms and inflammation using tools such as faecal calprotectin and, where available, intestinal ultrasound (IUS).¹

Fiona Chan

​

Secure the Right Balance with Anabolic Agents for Osteoporotic Patients

Osteoporosis can be likened to a “reverse tumour”: a progressive bone disease marked by declining bone mass and density1. In Hong Kong, with its rapidly ageing population and world-leading life expectancy, the burden of osteoporosis only grows in concern2. Zuellig Pharma convened a scientific symposium gathering leading orthopaedic surgeons from Hong Kong and overseas, to illuminate the key role Forteo plays in fracture risk reduction and bone mineral density.

​

​

The Roles of Tenofovir Alafenamide in Ensuring Sustainable Control of CHB with Concomitant MAFLD

Apart from the chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV), the role of non-viral risk factors in the development of chronic liver diseases has attracted clinical concern. Particularly, the co-existence of metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with chronic hepatitis B (CHB) is increasingly common, and the associated impact has been recognized1. Nonetheless, the interplay between CHB and MAFLD has been poorly studied. To uncover the essence of managing CHB patients with co-existing MAFLD in local settings, Dr. Vincent Wong discussed the clinical challenges of the dual etiology of CHB and MAFLD and shared his opinions on optimizing the management of the disease.

Dr. Roy Lau

​

Lower Bone Mineral Density Associated with Higher Risk of Atherosclerotic Cardiovascular Disease in Asian Women

Atherosclerosis and osteoporosis are major age-related diseases, predominantly contributing to significant morbidity and mortality in women. Osteoporosis is generally characterised by low bone mineral density and bone structure deterioration. A rece...

Yan Chiu

Aug 25, 2021

Time to Accelerate New Products with Sanofi!

Sanofi, a French pharmaceutical company intend to introduce more innovative treatments into the local market as a result of recent government incentives and encouraging steps to accelerate the introduction of breakthrough medications. Last year, San...

Moshin Roshan

Apr 26, 2024

Lower Cardiorespiratory Fitness Associated with Higher Psoriasis Risk

Psoriasis is a chronic immune-mediated disease of the skin, with wide dermatological manifestations, most commonly involving erythematous, scaly plaques on the extensor surfaces of the joints, whereas psoriatic arthritis is also a common coexisting ...

Yan Chiu

Sep 1, 2021

FEATURED

EVENT HIGHLIGHTS

Hong Kong Fertility Preservation Workshop 2025: An activity under the Sanming Project of Medicine, Shenzhen

Organisers: The first day of workshop commenced with a warm welcome address by Prof. Ko Ka Yee Jennifer, setting the stage for an engaging program. Session One explored the evolution and modern practices of ovarian tissue cryopreservation. Prof. And...

Michelle Lee

Jun 13, 2025

Anchored in Hong Kong, Connecting the Greater Bay Area - From GBA to Global Health Summit

The global healthcare industry has become an integral part of China's new-quality productive forces. Particularly, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) is emerging as a global medical hub, boasting unique strengths in research, c...

Dr. Roy Lau

Apr 11, 2025

Hong Kong Sets New Record for “Most Healthcare Professionals and Kidney Patients Doing Health Exercises Simultaneously”

Promoting Physical Activity to Prevent Chronic Diseases on World Kidney Day On the morning of March 8, the Kowloon Park Piazza was filled with energy and joy, as more than 1,000 healthcare workers, kidney patients and their caregivers joined hands&m...

Dr. Feng Xue

Apr 28, 2026

The Immune Reset Revolution: CAR T-Cell Therapy Takes Centre Stage at EULAR 2026

Dr. Feng Xue

​

Hope in Motion: Clinical Progress and Social Support for Parkinson’s

Parkinson’s disease (PD) remains an incurable neurological disorder that disproportionately affects the aging population, profoundly impacting patients and their families. In pursuit of better management strategies, extensive research and clinical trials are underway. Many of these efforts have yielded promising breakthroughs that offer hope for improving quality of life, despite the limited understanding of PD’s underlying aetiology. This article highlights recent advances in PD management, including novel therapeutic approaches such as α-synuclein–targeted treatments, induced pluripotent stem cell replacement therapy, drug repurposing, deep brain stimulation, and non-pharmacological interventions. While much of this research is still in progress, these developments provide an encouraging outlook for the future of PD treatment and underscore the need for sustained, large-scale, and rigorous investigation to move beyond the current status quo.

Andrew Chan

​

A Silent Killer No More: How New Discoveries Are Changing Pancreatic Cancer Outcomes

For decades, pancreatic cancer has been one of the most feared diagnoses in medicine. Often called a “silent killer,” the disease typically develops with few symptoms and is frequently discovered only after it has reached an advanced stage. As a result, survival rates have historically lagged behind those of most other major cancers. However, a wave of scientific breakthroughs is beginning to change this narrative. Advances in imaging, biomarker discovery, genetic profiling, surgical techniques, immunotherapy, and precision medicine are creating new opportunities for earlier detection and more effective treatment. Most notably, the emergence of targeted therapies aimed at KRAS-driven tumours—long considered impossible to treat—has generated unprecedented optimism. Among these innovations, daraxonrasib has attracted worldwide attention after a major clinical trial demonstrated a near doubling of median overall survival in patients with previously treated metastatic pancreatic cancer. These developments suggest that pancreatic cancer may be entering a new era in which outcomes are steadily improving and personalised treatment becomes the standard of care. This article explores the scientific advances transforming pancreatic cancer care and examines what they could mean for patients in the years ahead.

Dr. Feng Xue

​

Uncovering the Tricks of the Silent Thief of Sight

Glaucoma is a progressive optic neuropathy characterised by visual field loss and structural damage to the optic nerve. The disease is a leading cause of irreversible blindness worldwide, affecting about 3.5% of individuals aged between 40 and 80 years1. While glaucoma-associated visual field loss may be asymptomatic until the late stages, the disease is commonly known as a silent thief of sight. Although early diagnosis of glaucoma remains a clinical challenge, recent advancements in therapeutics have significantly improved patient outcomes. In particular, laser treatment has been advocated to be safe and effective in managing glaucoma. In a recent sharing, Dr. Lai Sum Wai Isabel highlighted the pathophysiology of glaucoma and shared her insights into managing the disease.

Dr. Roy Lau

Dec 19, 2024

1770793011XUNFv.jpg

Clinical Trial Snapshot: Enhancing Motor Function in SMA with Apitegromab

Jun 13, 2025

1770793011XUNFv.jpg

MATTERHORN Trial Revealed: Durvalumab Boosts Survival in Resectable Gastric Cancer

Aug 14, 2025

1770793011XUNFv.jpg

Melatonin: Hear Failure's Friend or Foe

Dec 19, 2025

1770793011XUNFv.jpg

Enter an Era of Optimism and Clinical Impact with CGRP Migraine Therapy

Feb 11, 2026

1770793011XUNFv.jpg

LDL-C Management with Inclisiran in Patients with Recent Acute Coronary Syndrome (ACS): A Clinical Trial Snapshot of the VICT

Oct 24, 2025

Courses For Doctors

ECG CME FEBRUARY 2026 (0.5 CME Points)

CME:

0.5 point

Deadline:

28 February 2026
This ECG CME was prepared by Dr. Pun Chiu On, Specialist in Cardiology.

Feb 11, 2026

ECG CME DECEMBER 2025 (0.5 CME Points)

CME:

0.5 point

Deadline:

28 January 2026
This ECG CME was prepared by Dr. Pun Chiu On, Specialist in Cardiology.

Dec 19, 2025

ECG CME OCTOBER 2025 (0.5 CME POINTS)

CME:

0.5 point

Deadline:

28 November 2025
This ECG CME was prepared by Dr. Pun Chiu On, Specialist in Cardiology.

Oct 24, 2025

The Roles of Undenatured Type II Collagen Supplementation in Maintaining Joint Health

CME:

1 point

Deadline:

20 July 2025
Joint disease is frequently observed in primary care settings, with osteoarthritis (OA) being the most common condition.

Jun 13, 2025

bottom of page